Attenuated
The present invention provides attenuated M haemolitica strains that elicit an immune response in animal against M haemolitica , compositions comprising said strains, methods of vaccination against M haemolitica , and kits for use with such methods and compositions. The invention further provides multi-valent vaccines, which provide protective immunity when administered in an effective amount to animals susceptible to “shipping fever” or bovine respiratory disease.
1. A kit comprising a first container comprising an attenuated M. haemolytica and instructions on administering said attenuated M. haemolytica to an animal, wherein said attenuated M. haemolytica comprises a deletion within the LktCA gene locus encoding acylase (LktC) and leukotoxin A (LktA); and wherein said attenuated M. haemolytica bacterium secretes a truncated LktCA having an amino acid sequence set forth in SEQ ID NO: 18.
2. The kit of claim 1 , further comprising a second container comprising a pharmaceutically or veterinarily acceptable carrier.
3. The kit of claim 1 , wherein said attenuated M. haemolytica has the designation serotype A1 D153.
4. The kit of claim 1 , wherein said attenuated M. haemolytica has the designation serotype A6 D174.
5. The kit of claim 1 , wherein said attenuated M. haemolytica further comprises a polynucleotide having a sequence of SEQ ID NO: 16 or SEQ ID NO: 17.
6. A kit comprising (i) a first container comprising an attenuated M. haemolytica serotype A1 D153 comprising a mutated LktCA gene locus that encodes a truncated LktCA having an amino acid sequence set forth in SEQ ID NO: 18, (ii) a second container comprising an attenuated M. haemolytica serotype A6 D174 comprising a mutated LktCA gene locus that encodes a truncated LktCA having an amino acid sequence set forth in SEQ ID NO: 18, and (iii) instructions on administering said attenuated M. haemolytica to an animal.
7. The kit of claim 6 , further comprising a third container comprising a pharmaceutically or veterinarily acceptable carrier.
8. The kit of claim 6 , wherein said attenuated M. haemolytica serotype A1 D153 further comprises a polynucleotide having a sequence of SEQ ID NO: 16 or SEQ ID NO: 17, and wherein said attenuated M. haemolytica serotype A6 D174 further comprises a polynucleotide having a sequence of SEQ ID NO: 16 or SEQ ID NO: 17.